Mueed Z, Tandon P, Maurya SK, Deval R, Kamal MA, Poddar NK
For people comparing metabolic research areas, related reading categories include weight-management articles, type 2 diabetes articles, and broader diabetes articles
LIFT-AD Phase 2/3 Failure The larger LIFT-AD trial fails both primary and key secondary endpoints, raising questions about the clinical viability of fosgonimeton
Overall, our results suggest that the AP is responsible for the appetite-suppressing effects of GIPR agonism but that GIP receptors in the hypothalamus underlie the ability of GIPR antagonism to enhance the weight loss effects of GLP-1R and amylin receptor agonists
Journal of Korean Medical Science, 25(5), 776-780
Simple guide: What is GLOW peptide, and how is KLOW different